title: Primary gastric lymphoma: a clinical and therapeutic evaluation of 82 patients.
abstract: Eighty-two patients with primary gastric (IE, II1E, and II2E) non-Hodgkin's lymphoma according to the Musshoff's staging system were treated with combined modality including surgery with/without radiotherapy between January 1985 and December 1991. According to the Updated Kiel classification 54 had high-grade histologic subtypes and 28 low-grade. The strategy throughout the study was to resect primary tumor: all patients underwent gastrectomy, 40 subtotal and 42 total gastrectomy. The resection permitted complete surgical staging utilizing three pathologic features: disease confined within or beyond the serosa, negative/positive regional lymph nodes, and negative/positive surgical margins. If there was no evidence of these pathologic factors, the patients who underwent surgery alone received no further radiotherapy. On the other hand, all patients who presented at least one of three pathologic factors were treated with adjuvant radiotherapy after the resection. All except 14 patients presented at least one of the pathologic features and 50 (61%) patients had involvement of the whole gastric wall. Radiotherapy included the gastric bed and para-aortic lymph nodes and, for the patients, who had positive regional lymph nodes in combination with the complete involvement of the gastric wall, the irradiation included the whole abdominal approach. The complete response rate was 97% and the 9-year disease-free survival was 93%. All but one of the 5 relapses occurred within 18 months stressing the need for more specific staging. Gastric resection with/without radiotherapy may still represent the primary therapeutic procedure in early stage gastric non-Hodgkin's lymphoma.
authors.affiliation: Institute of Hematology L. e A. Seràgnoli, University of Bologna, Italy.
authors.forename: P L
authors.initials: PL
authors.lastname: Zinzani
authors.forename: G
authors.initials: G
authors.lastname: Frezza
authors.forename: M
authors.initials: M
authors.lastname: Bendandi
authors.forename: E
authors.initials: E
authors.lastname: Barbieri
authors.forename: F
authors.initials: F
authors.lastname: Gherlinzoni
authors.forename: S
authors.initials: S
authors.lastname: Neri
authors.forename: A
authors.initials: A
authors.lastname: Baldissera
authors.forename: M
authors.initials: M
authors.lastname: Salvucci
authors.forename: L
authors.initials: L
authors.lastname: Babini
authors.forename: S
authors.initials: S
authors.lastname: Tura
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005743:Gastrectomy; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy; D015996:Survival Rate